RemSleep Holdings, Inc. filed a Form 10-Q with the SEC on November 20, 2026, covering the quarterly and nine-month periods ended September 30, 2026, disclosing zero operating revenue and a widening stockholders' deficit for the period.

Key Highlights

  • No revenue recorded: The company reported $0 in operating revenue for both the three-month and nine-month periods ended September 30, 2026, compared to $7,454 and $12,278, respectively, in the same periods of 2025.
  • Net loss of $405,103: The nine-month net loss was $405,103, versus a net loss of $2,685,406 for the nine months ended September 30, 2025.
  • Stockholders' deficit of $159,693: Total stockholders' equity turned negative at $(159,693) as of September 30, 2026, compared to positive equity of $32,062 at December 31, 2025.
  • Cash declined sharply: Cash and bank balances fell to $23,947 as of September 30, 2026, from $214,514 at December 31, 2025.
  • Share count increased: Common shares issued and outstanding rose to 1,827,016,724 as of September 30, 2026, from 1,659,190,126 at December 31, 2025, with 167,826,616 shares issued for debt conversion during the period.
  • Accumulated deficit reached $18,696,159: The accumulated deficit grew to $18,696,159 as of September 30, 2026, from $18,291,056 at December 31, 2025.

RemSleep Holdings Financial Position and Results for the Nine Months Ended September 30, 2026

According to the filing, RemSleep Holdings (OTC Pink:RMSL) generated no operating revenue for either the three-month or nine-month periods ended September 30, 2026. This compares to revenues of $7,454 and $12,278 for the corresponding three- and nine-month periods of 2025. The company reported a gross profit of $0 for both 2026 periods, down from $7,426 and $11,650 in the prior-year comparable periods.

Total operating expenses for the nine months ended September 30, 2026 were $280,985, the filing disclosed, driven primarily by general and administrative expenses of $229,769 and compensation expenses of $44,140. This represents a significant reduction from $2,558,786 in total operating expenses for the nine months ended September 30, 2025, which included $2,248,000 in compensation expenses. The company reported a loss from operations of $280,985 for the nine-month period ended September 30, 2026, compared to $2,547,136 for the same period in 2025.

Other expense items for the nine months ended September 30, 2026 included interest expenses of $52,578, a loss on issuance of convertible debt of $79,898, and a loss on conversion of debt of $28,146, partially offset by a gain from the change in fair value of derivative of $36,503, according to the filing. Total liabilities stood at $319,199 as of September 30, 2026, against total assets of $159,506, resulting in a net deficit position. The company's convertible notes payable were listed at $55,139, with an associated derivative liability of $78,038. Common stock authorized remains at 3,000,000,000 shares, and the company disclosed that as of November 13, 2026, there were 1,827,016,742 shares of common stock outstanding.

What Was Disclosed

RemSleep Holdings filed its unaudited quarterly report for the period ended September 30, 2026, disclosing zero revenue, a nine-month net loss of $405,103, a stockholders' deficit of $159,693, and a cash balance of $23,947 as of the period end.